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Severity scoring system for paediatric FMF
Gokhan Kalkan, Erkan Demirkaya and Seza Ozen
In a recent commentary in Nature Reviews
Rheumatology, Livneh1 discussed paediatric
scoring systems for familial Mediterranean
fever (FMF; Severity score system for paedi‑
atric FMF, Nat. Rev. Rheumatol. 8, 309‑310;
2012) in relation to our recent manuscript
on the topic. 2 We consider sharing our
opinion with the scientific community as
an ethical obligation and, therefore, would
like to respond to the criticisms in the
Livneh commentary.1
One of the key messages of our study
was the lack of consistency between the
current severity scoring tools for paedi‑
atric FMF. However, this finding would
not necess arily make studies of sever‑
ity scoring systems questionable. In this
regard, Ozen et al.3 examined the environ‑
mental effects on the severity of childhood
FMF by adjusting Mor 4 and Pras5 scoring
systems to children, and did not compare
the consistency of different scoring sys
tems, but compared the results of each
scoring system according to the country of
residence. Ozen et al.3 also demonstrated
disagreement between the two scoring
systems, although they did not specifi‑
cally mention such finding. For example,
the percentage of patients with severe dis
ease in Turkey was 78.2% based on modi‑
fied scoring system by Mor and colleagues.
However, the percentage of patients with
severe disease was only 34.5% according to
modified Pras scoring system.

Another area of criticism in the Livneh
commentary was the modification of the
colchicine dose, in that it might have biased
our results. The clinician’s decision regard‑
ing the dose of colchicine administered for
adults is primarily related to disease sever‑
ity. However, age and weight are the main
determinants of colchicine dosing in chil‑
dren. Therefore, it is evident that the amount
of dosing might not be a direct indicator of
disease severity for an infant as compared
with an adult. Moreover, colchicine dose by
itself as a measure of disease severity might
not be the best choice in light of current
knowledge of pharmacogenetics; increase
in colchicine dose used can be due to the
pharmacogenetic profile of an individual,
rather than an increase in disease severity. In
addition, there is a subgroup of patients who
do not respond to colchicine but do respond
to other therapies (such as as interleukinreceptor blockers). In this regard, severity
scoring systems, irrespective of their modi‑
fication status, will probably miss a patient
with severe disease.
Lastly, we are pleased to hear Dr Livneh’s
support for an international consortium to
establish a severity scoring system specifi‑
cally for children with FMF. The distinct
course of the disease in the paediatric age
group decreases the utility of the scoring
systems of Mor et al.4 and Pras et al.,5 which
were originally developed for adults with
FMF. There are many qualitative FMF
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researchers across the Mediterranean basin.
We will be supportive of any initiative that
aims to bring expert experiences together.
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